INTRODUCTION
Endothelial progenitor cells (EPCs) mainly originate from the bone marrowderived cells. They possess the ability to differentiate into mature endothelial cells (ECs) and are involved in blood vessel formation [1] . EPCs play a fundamental role in neoangiogenesis and tumor angiogenesis [2, 3] . Neovascularization contributes to several pathological conditions, including tumor growth, diabetes, atherosclerosis and inflammatory processes. Tumors usually arise from small avascular masses and induce neovascularization in order to acquire nutrients for continued growth and metastatic spread. Some studies have reported that EPCs play a key role in the growth of early tumors and metastatic lesions by mediating the so-called angiogenic switch [2] [3] [4] [5] [6] . The number of EPCs in the peripheral blood has been found to be higher in patients with various types of cancer, including breast cancer [7] , lung cancer [8] , gastric cancer [9] , liver cancer [10] and gynecological cancers [11] , than in healthy individuals. This indicates that EPCs contribute to cancer progression and can be targeted for early diagnosis and monitoring of patient response to treatment. However, the mechanism underlying the regulation of the functional activity of EPCs and the key factors involved in the mechanism remain unclear. Neoangiogenesis (sprouting, bridging and intussusceptive growth from extant vessels) plays a pivotal role in tumor development. Vascular endothelial growth factor (VEGF) is vital for neovascularization from mature ECs [12] . Autocrine VEGFs released by ECs and EPCs maintain vascular balance and stability [13, 14] . At least four molecular pathways are involved in the regulation of this process. They involve the following key components: platelet-derived growth factor B (PDGF-B), PDGF receptor-β (PDGFR-β), sphingosine-1-phosphate (S1P) and endothelial differentiation sphingolipid G-protein-coupled receptor 1 (S1PR1) [12] . S1P is a serum-derived bioactive lipid metabolite that is present in the blood and in most tissues where cellular processes and biological activities that play key roles in inflammation and immune responses occur [15, 16] . S1P is an agonist of five specific G-protein-coupled receptors (S1PR1 through 5) that activate diverse downstream signaling pathways, and it has important intracellular (second messenger) activities [16] . It performs pleiotropic actions and is a proangiogenic signaling molecule that regulates neovascularization, provides tumor cells with oxygen and nutrients, and facilitates cell growth and survival [17, 18] . Several recent studies have reported the involvement of S1P in cancer development. In addition to contributing to the regulation of tumor cell survival, invasion and metastasis, S1P also plays an oncogenic role in colon cancer [19] [20] [21] [22] partially through interaction with components of several signaling pathways, such as PDGF-B, the VEGF receptors, and the epidermal growth factor (EGF) receptors [17, 23, 24] .
PDGFR was implicated in the autocrine stimulation of tumor growth and in paracrine stimulation of tumor-associated angiogenesis in a variety of human epithelial cancers [25] [26] [27] . For example, high PDGFR-β expression has been observed in ECs in breast cancers and gliomas [28, 29] . Recent studies showed that tyrosine kinase inhibitors, which block multiple kinases including PDGFR-β, enhance the effect of VEGF inhibitors [30] . This promotive effect may be caused by the reduced production of VEGF and/or tumor matrix molecules by PDGFR-β-positive perivascular cells [12] . A previous study reported the localization of PDGFR-β in the plasma membrane of EPCs and PDGF-BB-induced migration and angiogenesis of EPCs through the PI3K/Akt signaling pathway [31] . Serine/threonine kinase (Akt) is a key component of the signaling pathways that regulate multiple cellular processes, such as cell survival, motility, tissue invasion and angiogenesis [32] . Activation of the Akt signaling pathway has been reported to be involved in various types of human cancer [33] [34] [35] . Since the first report of simvastatin-induced phosphorylation of Akt in EPCs [36] , several studies have shown that Akt signaling is also required upon stimulation with other agents, including in VEGF and PDGF-BB [31, 37] . It has been reported that S1P can mediate the activation of the Akt signaling pathway in various cell types and via the sphingosine-1-phosphate receptor 3 (S1PR3), can stimulate the functional capacity of EPCs. [38] . Studies have shown that Akt phosphorylation induced by S1P via S1PR3 requires PDGFR in the S1PR3 cells [39] . Based on the available information on S1P, S1PR3, PDGFR-β and the Akt signaling pathway and on the biological functions of EPCs, we hypothesized that S1P can induce the migration and angiogenesis of EPCs through the Akt signaling pathway via S1PR3/PDGFR-β. To test this hypothesis, we examined whether the S1PR3/PDGFR-β/Akt signaling pathway is involved in S1P-induced migration and angiogenesis of EPCs. 
MATERIAL AND METHODS

Ethical statement
Cell culture and characterization
Mouse spleen-derived EPCs were cultured as previously described [31] . Briefly, spleen-derived mononuclear cells (MNCs) were isolated by density gradient centrifugation (Lymphoprep 1.077; Axis-Shield PoC AS). After three rinses, the cells were seeded on fibronectin-coated cell culture flasks and cultured in Dulbecco's modified Eagle medium/nutrient mixture F-12 (DMEM/F-12; Gibco BRL) supplemented with 20% fetal calf serum (FCS; Gibco BRL), 10 ng/ml VEGF (R&D Systems), 100 U/ml penicillin, and 100 U/ml streptomycin in a 5% CO 2 incubator at 37ºC. After 4 days of culturing, the medium was changed every 3 days. The non-adherent cells were removed by washing with phosphatebuffered saline (PBS). Only the adherent cells were used for further experiments. For characterization, differentiating cells after 4 days of culture were incubated with 2.4 μg/ml DilAc-LDL (Invitrogen) at 37ºC for 4 h and fixed with 4% paraformaldehyde (PFA) for 10 min. After being rinsed with PBS, the cells were incubated with 10 μg/ml FITC-UEA-1 (UEA: Ulex europaeus agglutinin; Sigma-Aldrich) for 1 h. Finally, the cells were counterstained with 1 μg/ml of 4',6-diamidino-2-phenylindole (DAPI; Beyotime) for 5 min. Triple-stained cells positive for DilAc-LDL, UEA-1, and DAPI were identified as EPCs. In addition, the expressions of EC markers (VEGFR-2) and progenitor cell markers (Sca-1) were evaluated via immunofluorescence. The cells were fixed with 4% PFA for 15 min. After three rinses with PBS, the cells were permeabilized with 0.1% Triton X-100 for 20 min. EPCs were first incubated with anti-VEGFR-2 primary mAb (1:100; eBiosciences) or anti-Sca-1 primary mAb (1:100; abCAM) and then with a Cy3-labeled secondary antibody (Beyotime) or FITC-labeled secondary antibody (Beyotime). DAPI was used to stain the cell nuclei. Images were obtained using laser scanning confocal microscopy (LSCM; Leica).
The groups and treatment of EPCs in biological activity assay
Our previous study revealed PDGF-BB-induced proliferation, migration and angiogenesis of EPCs through the PDGFR-β/PI3K/Akt signaling pathway [31] . In this study, we further analyzed whether the PDGFR-β/Akt signaling pathway plays a role in the S1P-induced migration and angiogenesis of EPCs. The following six groups of EPCs were created: control, S1P, S1P+CAY10444, S1P+AG1295, S1P+CAY10444+AG1295 and S1P+sc-221226. The S1PR3 antagonist CAY10444 (Cayman Chemical) and a selective inhibitor of PDGFR AG1295 (Sigma-Aldrich) and Akt inhibitor sc-221226 (Santa Cruz Biotechnology) were used to inhibit the activation of the PDGFR-β or the Akt signaling pathway. In this study, S1P (200 nM), CAY10444 (10 μM), AG1295 (20 μM) and sc-221226 (20 μM) were used as described in previous reports [31, 38] .
Enzyme-linked immunosorbent assay (ELISA) for secreted VEGF
The concentrations of VEGF in the cell supernatants were measured using an ELISA kit (R&D Systems) according to the manufacturer's protocol. To compare the expression levels of VEGF among the six groups of EPCs, the groups were either pretreated or not treated with CAY10444, AG1295 or sc-221226 for 30 min each, followed by treatment with or without S1P (200 nM) in DMEM/F-12. The culture medium was collected after 72 h and centrifuged at 6,000 × g at 4ºC for 10 min. The samples were analyzed in triplicate and appropriately diluted to ensure that the measured values were within the concentration range of the standard curve.
Cell migration assay
A Corning Costar Transwell system containing 8-μm polycarbonate filter inserts in 24-well plates was used to examine the migration of EPCs. EPCs (2 × 10 5 ) from the six groups with or without pretreatment with CAY10444, AG1295 or sc-221226 for 30 min each in 200-ml serum-free DMEM/F12 were placed in the upper chamber. DMEM/F12 containing 10% FCS (500 μl) with or without S1P was filled in the lower chamber. After 12 h, the cells at the bottom of the Transwell membrane were fixed with 4% PFA and stained with DAPI for 5 min. The numbers of migrating cells on the bottom of the Transwell system in five randomly selected high power fields (HPFs ×200) were counted under a fluorescence microscope. The results were representative of five independent experiments.
Cell tube-formation assay
The participation of EPCs in the formation of tube-like structures was assayed using a Chemicon In Vitro Angiogenesis Assay Kit. EPCs were treated as in the migration, examined, harvested, resuspended, and then seeded onto 96-well plates coated with 50 μl of the diluent EC Matrix solution at a cell density of 1 × 10 4 /well. The cells were incubated at 37ºC for 6 h, EPC tube-like formation was examined by microscopy, and the visual patterns were defined based on the pattern/value association criterion (Table 1) . Five randomly selected HPFs (200×) per well were assessed, and the values were averaged. 
Western blotting
EPCs were cultured in 6-well plates and allowed to grow to 80% confluence before stimulation for 30 min with CAY10444 (10 μM), AG1295 (20 μM), CAY10444 (10 μM) and AG1295 (20 μM), or sc-221226 (30 μM) and S1P (200 nM) in DMEM/F-12 (supplemented with 1% FBS and without endothelial cell growth supplement). The protein concentration of cell lysates was estimated using the Bradford method, and the proteins were transferred onto polyvinylidene fluoride (PVDF) membranes. The membranes were blocked with 5% non-fat milk, probed with anti-PDGFR-β, antiphospho-PDGFR-β (1:500; Abcam), antiAkt, anti-phospho-Akt (1:500; Cell Signaling Biotechnology) or anti-GAPDH (1:1000; Cell Signaling Biotechnology), and then stained with horseradish peroxidase-coupled secondary antibodies. The protein bands were visualized via enhanced chemiluminescence (Amersham Pharmacia Biotech) and quantified by using the Quantity One Software (Bio-Rad). An equal volume of cell lysate was run on an 8% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and electrotransferred to a PVDF membrane (ThermoFisher) using the iBot Gel Transfer System (Invitrogen).
Statistical analysis
All data were expressed as means ± standard deviation (SD) of at least three repeated experiments. Statistical analyses were performed using the SPSS 13.0 software (IBM). Comparisons between the groups were performed using a one-way analysis of variance (ANOVA). p < 0.05 was considered statistically significant.
RESULTS
Characterization of spleen-derived EPCs
To identify the purity and phenotype of EPCs from mouse spleen, the attached cells were characterized using immunofluorescence after 4-7 days of cell culturing. Most of the MNCs (90.94 ± 2.23%) were positively stained for DilAc-LDL, UEA-1 lectin binding and DAPI (Fig. 1A-D) . In addition, 70.11 ± 5.1% of the MNCs expressed the endothelial cell marker VEGFR-2 ( Fig. 1E ) and 83.33 ± 3.57% expressed the mouse stem-cell marker Sca-1 (Fig. 1F) . These results confirmed the successful isolation and culturing of mouse spleen-derived EPCs.
Secretion of VEGF by EPCs
EPCs have been demonstrated to release angiogenic growth factors such as VEGF [14] . Therefore, we investigated whether S1P, AG1295, CAY10444 and sc-221226 can affect the secretion of VEGF by EPCs by comparing the protein concentration of VEGF in the supernatant of the culture medium. Our results indicated that, in the S1P group, the concentration of soluble VEGF increased significantly to 455.67 ± 42.74 pg/ml. However, the S1P+CAY10444 group (228.01 ± 41.58 pg/ml), S1P+AG1295 group (251.27 ± 80.21 pg/ml), S1P+CAY10444+AG1295 group (216.67 ± 30.09 pg/ml) and S1P+sc-221226 group (268.71 ± 53.37 pg/ml) showed significantly decreased VEGF secretion (Fig. 2) . These results revealed an important relationship between S1P, S1PR3, PDGFR-β, Akt and VEGF in EPCs.
The role of the S1PR3/PDGFR-β/Akt pathway in S1P-induced migration of EPCs We investigated whether the S1PR3/PDGFR-β/Akt signaling pathway is required for S1P-induced EPC migration using the Transwell system. Comparison of the control group (Fig. 3A) and the S1P group revealed S1P-induced EPC migration (Fig. 3B) . By contrast, S1P-induced migration was significantly inhibited by pretreatment with CAY10444 (Fig. 3C) , AG1295 (Fig. 3D) , CAY10444+AG1295 (Fig. 3E ) or sc-221226 (Fig. 3F) . These results revealed that the S1PR3/PDGFR-β/Akt signaling pathway participated in the S1P-induced migration of EPCs (Fig. 3G) . The role of the S1PR3/PDGFR-β/Akt pathway in S1P-induced tubeformation of EPCs Next, we used the In Vitro Angiogenesis Assay Kit to detect whether the S1PR3/PDGFR-β/Akt signaling pathway is required for S1P-induced EPC angiogenesis. Comparison of the control group (Fig. 4A ) and the S1P group revealed S1P-induced EPC tube-formation (Fig. 4B) . However, S1P-induced tube-formation was significantly inhibited by pretreatment with CAY10444 (Fig. 4C) , AG1295 (Fig. 4D) , CAY10444+AG1295 (Fig. 4E ) or sc-221226 (Fig. 4F) . These data suggested that the S1PR3/PDGFR-β/Akt signaling pathway participated in the S1P-induced tube-formation of EPCs (Fig. 4E) . 
Various inhibitors attenuate S1P-stimulated phosphorylation of PDGFR-β and Akt
In this study, we determined whether S1P activates the S1PR3/PDGFR-β/Akt/signaling pathway in EPCs. The phosphorylation levels of PDGFR-β and Akt were examined by western blotting of EPCs (Fig. 5A ). Exogenous stimulation with S1P leads to phosphorylation of PDGFR-β and Akt. We found that phosphorylation of PDGFR-β induced by S1P was not affected by pretreatment with the S1PR3 inhibitor CAY10444 (10 μM; Fig. 5B ), but the increase in phosphorylation of Akt was significantly blocked (p < 0.05; Fig. 5C ).
We also found that the PDGFR inhibitor AG1295 (20 μM) significantly blocked the increase in phosphorylation of PDGFR-β (p < 0.01; Fig. 5B ) and Akt (p < 0.05; Fig. 5C ). At the same time, CAY10444 combined with AG1295 significantly blocked the increase in phosphorylation of PDGFR-β (p < 0.05; Fig. 5B ) and Akt (p < 0.01; Fig. 5C ) in EPCs in response to S1P (200 nM) stimulation, indicating that S1PR3 and PDGFR-β was critical for S1P-mediated activation of Akt signaling. In addition, the Akt inhibitor sc-221226 (30 mM) significantly blocked the phospho-Akt (p < 0.01; Fig. 5C ) in EPCs in response to S1P (200 nM) stimulation. These results have confirmed that S1P treatment activates Akt through S1PR3 and PDGFR-β in EPCs. 
DISCUSSION
In this study, we found that S1P induces the migration and angiogenesis of EPCs through the Akt signaling pathway via S1PR3 and PDGFR-β. We observed that S1P significantly increases VEGF secretion from EPCs and the selective inhibition of S1PR3, PDGFR or Akt can decrease VEGF levels. VEGF plays a key role in the angiogenesis of pathological conditions such as diabetes, atherosclerosis and cancer. Indeed, most of the current anti-angiogenic strategies for cancer therapy are based on blocking VEGF functions, and anti-VEGF agents have been successfully used for the treatment of certain human cancers [40, 41] . However, anti-VEGF monotherapy had the limitation of drug resistance, suggesting that non-VEGF angiogenic factors contribute to the growth of blood vessels [42] . Recent clinical trials using VEGF-A165 for the treatment of ischemic disease revealed the limitations of such a unifactorial approach. The blood platelets mainly release S1P to promote the repair of damaged vessels after percutaneous coronary intervention or during atherosclerosis. However, there is no solid evidence for the process of cancer development being similar. Our results indicate a new line of thought for anti-cancer vessel development. PDGFR has been implicated in the autocrine stimulation of tumor growth and in the paracrine stimulation of tumor-associated angiogenesis in a variety of human epithelial cancers [25] [26] [27] . We found that PDGF-BB increases the proliferation and angiogenesis of EPCs through PDGFR-β. Furthermore, tyrosine kinase inhibitors, which block multiple kinases including PDGFR-β, enhance the effect of VEGF inhibitors [11] . We noticed that the levels of several growth factors, including VEGF, S1P, PDGF-BB and EGF, increase in patients with cancer. These could affect the amount and biological activity of EPCs and the development of cancer. Since S1P and PDGF-BB can increase VEGF release in EPCs and since VEGF exerts an autocrine effect on EPCs, we believe that S1P and PDGF-BB may be the initiation factors that play a role in cancer development. However, whether these factors exert a synergistic effect on EPCs remains unclear. S1P can induce extravillous trophoblast invasive phenotypic changes in vitro and the promotion requires activation of MEK-ERK and is dependent on the axis of S1P/S1PR1 [43] . We have reported that the PI3K/Akt signaling pathway participates in PDGF-BB-induced proliferation, migration and angiogenesis of EPCs [31] . We conclude that most activation of S1P for EPC is suppressed when we selectively block the PDGFR-β/Akt signaling pathway. This also shows that S1P is partially dependent on the PDGFR-β/Akt signaling pathway during the processing of increasing EPC biological activity. The migratory responses or angiogenic activities of ECs have been reported to be promoted via the receptors S1PR1 or S1PR3 [1, [10] [11] [12] . S1P is also implicated in the regulation of tumor cell survival, invasion, and metastasis [9] . It has been demonstrated in several cell types that the cross-talk between PDGF and S1P signaling pathways can affect the function of the cells [39, 44, 45] . For rat VSMCs, the PDGFR-S1PR1 pathway is predominantly dedicated to cell growth while the PDGFR-S1PR2 pathway is mainly responsible for cell migration stimulation [46] . The following need clarification: which receptor or receptors were expressed on the surface of mouse EPCs; the relationships between these receptors; and which type of S1PR plays the dominant role during the process of S1P-induced EPC migration and vessel formation. Our study demonstrated that S1PR3/PDGFR-β and Akt play an important role following S1P stimulation of EPCs and that there is potential in targeting molecules in stimulated EPCs for cancer treatment. To the best of our knowledge, this is the first report on the mechanisms underlying S1P signaling-mediated physiological changes and the first to show that PDGFR-β-S1PR3 may play some role in Akt signaling in EPCs. The relationship between the activation of the phosphorylation of PDGFR-β and Akt in EPCs warrants further investigation.
